UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403

Journal of clinical oncology, 2020-12, Vol.38 (34), p.4076-4085

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2021-07, Vol.27 (13), p.3630-3640

2021

Link zum Volltext

Verfügbarkeit prüfen

Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis

Lung cancer management, 2020-03, Vol.9 (1)

2020

Link zum Volltext

Verfügbarkeit prüfen

N-Acylglycine Amidation: Implications for the Biosynthesis of Fatty Acid Primary Amides

Biochemistry (Easton), 1999-03, Vol.38 (11), p.3235-3245

1999

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT191-CT191

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis

Inflammatory bowel diseases, 2018-12, Vol.24 (12), p.2494-2500

2018

Link zum Volltext

Verfügbarkeit prüfen

Sources of off-target effects of vagus nerve stimulation using the helical clinical lead in domestic pigs

Journal of neural engineering, 2020-08, Vol.17 (4), p.046017-046017

2020

Link zum Volltext

Verfügbarkeit prüfen

IgG4 related disease: Cousin, companion, or complication of Sjogren’s syndrome?

Pathology, 2022-03, Vol.54, p.S81-S81

2022

Link zum Volltext

Verfügbarkeit prüfen

Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11538-11538

2021

Link zum Volltext

Verfügbarkeit prüfen

An Injectable Neural Stimulation Electrode Made from an In‐Body Curing Polymer/Metal Composite

Advanced healthcare materials, 2019-12, Vol.8 (23), p.e1900892-n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18033-e18033

2022

Link zum Volltext

Verfügbarkeit prüfen

Cancer rarely travels alone: Addressing the accumulation of risk and early mortality for older adults with advanced lung cancer

Journal of geriatric oncology, 2023-07, p.101579-101579, Article 101579

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

Clinical and translational science, 2021-09, Vol.14 (5), p.1875-1885

2021

Link zum Volltext

Verfügbarkeit prüfen

The use of biomarkers in the treatment of non-small cell lung cancer

Expert review of precision medicine and drug development, 2016-01, Vol.1 (1), p.25-36

2016

Link zum Volltext

Verfügbarkeit prüfen

PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1465-S1465

2017

Link zum Volltext

Verfügbarkeit prüfen

676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A767-A767

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9024-9024

2021

Link zum Volltext

Verfügbarkeit prüfen

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood, 2020-11, Vol.136 (Supplement 1), p.20-21

2020

Link zum Volltext

Verfügbarkeit prüfen

Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function

Toxicological sciences, 2016-10, Vol.153 (2), p.396-408

2016

Link zum Volltext

Verfügbarkeit prüfen

Genomic-based treatment of patients with head and neck cancer

Expert review of precision medicine and drug development, 2020-09, Vol.5 (5), p.401-408

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluating end-of-life (EOL) care at the University of Rochester Medical Center (URMC) using quality oncology practice initiative (QOPI) metrics

Journal of clinical oncology, 2019-09, Vol.37 (27_suppl), p.12-12

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT086-CT086

2019

Link zum Volltext

Verfügbarkeit prüfen

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3011-3011

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

Risk of brain metastases in T1–3N0 NSCLC: a population-based analysis

N-Acylglycine Amidation: Implications for the Biosynthesis of Fatty Acid Primary Amides

Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis

Sources of off-target effects of vagus nerve stimulation using the helical clinical lead in domestic pigs

IgG4 related disease: Cousin, companion, or complication of Sjogren’s syndrome?

Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification

An Injectable Neural Stimulation Electrode Made from an In‐Body Curing Polymer/Metal Composite

Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84)

Cancer rarely travels alone: Addressing the accumulation of risk and early mortality for older adults with advanced lung cancer

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

The use of biomarkers in the treatment of non-small cell lung cancer

PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC

676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A)

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function

Genomic-based treatment of patients with head and neck cancer

Evaluating end-of-life (EOL) care at the University of Rochester Medical Center (URMC) using quality oncology practice initiative (QOPI) metrics

Abstract CT086: Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC

Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC

Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies

Suchergebnisse filtern